Wells Fargo downgraded Blueprint Medicines (BPMC) to Equal Weight from Overweight with a price target of $129, down from $143. The firm cites the pending takeover by Sanofi (SNY) for the downgrade.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BPMC:
- Blueprint Medicines announces data reinforcing sustained efficacy of AYVAKIT
- Blueprint Medicines price target raised to $129 from $88 at UBS
- Blueprint Medicines price target raised to $129 from $102 at Morgan Stanley
- Hold Rating on Blueprint Medicines Amid Sanofi Acquisition and Market Uncertainties
- Apple downgraded, Snowflake upgraded: Wall Street’s top analyst calls